<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05058443</url>
  </required_header>
  <id_info>
    <org_study_id>ShenzhenPH spine</org_study_id>
    <nct_id>NCT05058443</nct_id>
  </id_info>
  <brief_title>Denosumab and Osteoporotic Vertebral Compression Fracture</brief_title>
  <official_title>Attending Doctor of Shenzhen People's Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of bone mineral density and function at 1 year after vertebral kyphoplasty for&#xD;
      osteoporotic vertebral compression fractures with desomumab intervention: a parallel&#xD;
      double-blind randomized controlled clinical trial&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Conduct a single-center, double-blind, randomized controlled clinical trial according to&#xD;
      clinical Trial Reporting Standards (CONSORT).Bone mineral density and function were compared&#xD;
      1 year after PKP for osteoporotic vertebral compression fracture (OVCF) with desomumab versus&#xD;
      placebo in Shenzhen People's Hospital from September, 2021 to March, 2022.The study was&#xD;
      approved by Shenzhen People's Hospital and informed consent was signed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">September 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>age</measure>
    <time_frame>up to 12 months</time_frame>
    <description>participants age</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sex</measure>
    <time_frame>up to 12 months</time_frame>
    <description>participants sex</description>
  </primary_outcome>
  <primary_outcome>
    <measure>height</measure>
    <time_frame>up to 12 months</time_frame>
    <description>participants height cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>weight</measure>
    <time_frame>up to 12 months</time_frame>
    <description>participants weight kg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BMI</measure>
    <time_frame>up to 12 months</time_frame>
    <description>participants body mass index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>osteocalcin</measure>
    <time_frame>up to 12 months</time_frame>
    <description>osteocalcin in the N terminal molecular fragment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procollagen type 1 n-terminal propeptide (P1NP)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Procollagen type 1 n-terminal propeptide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-terminal cross-linked type 1 collagen terminal peptide( CTX)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>C-terminal cross-linked type 1 collagen terminal peptide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum total calcium</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Serum total calcium level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parathyroid Hormone</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Serum Parathyroid Hormone level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total phosphorus</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Serum total phosphorus level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total alkaline phosphatase (tALP)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Serum total alkaline phosphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Albumin</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Serum Albumin level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>lumbar spine bone mineral density</measure>
    <time_frame>up to 12 months</time_frame>
    <description>DEXA for lumbar spine bone mineral density</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hip bone mineral density</measure>
    <time_frame>up to 12 months</time_frame>
    <description>DEXA for Hip bone mineral density</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI of lumber</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Bone marrow edema and adjacent intervertebral disc were detected by MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numerical rating scale</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The NRS is a segmented numerical version of the VAS in which a respondent selects a whole number (0- 10) that best reflects the intensity of the pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>up to 12 months</time_frame>
    <description>VRSs use categories to differentiate pain intensity. There is a wide variability of terms used to describe each category and the rating may be divided into four (0 -3) or six (0 -5) categories. Patients score their pain intensity from absent (0) to severe (3) or from none (0) to very severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Roland-Morris Disability Questionnaire</measure>
    <time_frame>up to 12 month</time_frame>
    <description>The RDQ is a health status measure designed to be completed by patients to assess physical disability due to low back pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QUALEFFO 31</measure>
    <time_frame>up to 12 month</time_frame>
    <description>QUALEFFO 31 is a disease-specific measure of health related QoL applicable to patients with established vertebral osteoporosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol Five Dimensions Questionnaire</measure>
    <time_frame>up to 12 month</time_frame>
    <description>EQ-5D descriptive system is a preference-based HRQL measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Denosumab and Percutaneous Kyphoplasty</condition>
  <arm_group>
    <arm_group_label>dnosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desuzumab 60 mg subcutaneously /6 months, twice a year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneously /6 months, twice a year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>denosumab subcutaneously /6 months twice a year</description>
    <arm_group_label>dnosumab</arm_group_label>
    <arm_group_label>placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Must be age between 40 and 90 years old&#xD;
&#xD;
               -  X-ray diagnosis of 1-2 vertebral compression fractures&#xD;
&#xD;
               -  DEXA detected BMD T value less than -1&#xD;
&#xD;
               -  fracture history lasted within 6 weeks&#xD;
&#xD;
               -  MRI showed bone marrow edema of injured segment&#xD;
&#xD;
               -  Lower back pain, local spinous tenderness&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Must be able to have no posterior vertebral wall fracture&#xD;
&#xD;
               -  Must be able to have no intervertebral fissure&#xD;
&#xD;
               -  Must be able to have no infection&#xD;
&#xD;
               -  Must be able to have no malignancy&#xD;
&#xD;
               -  Must be able to have no neurological dysfunction&#xD;
&#xD;
               -  Must be able to have calcium level less than 2.13 mmol/L&#xD;
&#xD;
               -  Must be able to have no previous use of anti-osteoporosis drugs&#xD;
&#xD;
               -  Must be able to have no inability to perform magnetic resonance imaging&#xD;
&#xD;
               -  Must be able to have no prior back surgery&#xD;
&#xD;
               -  Must be able to have no other established contraindications for elective surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongyu Wang, Doctor</last_name>
    <phone>18241651300</phone>
    <email>wanghongyu790039663@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ShenzhenPH</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongyu Wang, Doctor</last_name>
      <phone>18241651300</phone>
      <email>wanghongyu790039663@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

